Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multi...
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
Research Cell Banks Produce Therapeutic Proteins in Just Eight Weeks as Validated in Oral Presentation on Integration of Berkeley Lights’ Beacon Optofluidic Platform with Selexis’ Workflow and Clon...